■阿尔茨海默病(AD)进展对患者健康相关生活质量(HRQoL)的影响,照顾者时间,和社会成本在早期AD没有很好的表征。
■为了评估认知变化与HRQoL的相关性,照顾者时间,以及超过36个月的社会成本,并评估减缓疾病进展对这些结果的影响。
这项事后分析包括来自36个月GERAS-US研究的淀粉样蛋白阳性轻度认知障碍(MCI)和轻度AD痴呆(MILDAD)患者。使用简易精神状态检查评分评估疾病进展。使用广义线性模型的系数估计与AD进展减慢相关的结果变化。
■在基线时,300例患者患有MCI,317例患有MILDAD。36个月内观察到的自然进展与:痴呆患者的Bath主观生活质量评估(BASQID)评分(HRQoL)下降5.1点,增加1,050小时的照顾者总时间,MCI的社会总成本为8504美元;BASQID评分下降6.6点,增加了1,929小时的照顾者总时间,以及每人$12,795的MILDAD总社会成本。AD进展减慢30%可能导致每人节省HRQoL下降,总护理时间,和社会总成本:MCI:1.5分,315小时,和$2,638;对于MILDAD:2.0点,579小时,和3974美元。
■在36个月内减缓AD进展可以减缓MCI和MILDAD患者的HRQoL下降并节省护理时间和社会成本。
UNASSIGNED: Impact of Alzheimer\'s disease (AD) progression on patient health-related quality of life (HRQoL), caregiver time, and societal costs is not well characterized in early AD.
UNASSIGNED: To assess the association of change in cognition with HRQoL, caregiver time, and societal costs over 36 months, and estimate the impact of slowing disease progression on these outcomes.
UNASSIGNED: This post-hoc analysis included patients with amyloid-positive mild cognitive impairment (MCI) and mild AD dementia (MILD AD) from the 36-month GERAS-US
study. Disease progression was assessed using the Mini-Mental State Examination score. Change in outcomes associated with slowing AD progression was estimated using coefficients from generalized linear models.
UNASSIGNED: At baseline, 300 patients had MCI and 317 had MILD AD. Observed natural progression over 36 months was associated with: 5.1 point decline in the Bath Assessment of Subjective Quality of Life in Dementia (BASQID) score (for HRQoL), increase in 1,050 hours of total caregiver time, and $8,504 total societal costs for MCI; 6.6 point decline in the BASQID score, increase in 1,929 hours of total caregiver time, and $12,795 total societal costs for MILD AD per person. Slowing AD progression by 30% could result in per person savings in HRQoL decline, total caregiver time, and total societal costs: for MCI: 1.5 points, 315 hours, and $2,638; for MILD AD: 2.0 points, 579 hours, and $3,974.
UNASSIGNED: Slowing AD progression over 36 months could slow decline in HRQoL and save caregiver time and societal cost in patients with MCI and MILD AD.